Despite advances in the understanding of complex AD pathogenesis such as amyloid-beta (Aβ) aggregation and tau protein pathology, the high rate of failure in clinical trials has hindered the development of disease-modifying therapies [6]. Here, MAPT is linked to Alzheimer disease.